RANI supply chain intelligence for Rani Therapeutics Holdings, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Rani Therapeutics Holdings, Inc. (RANI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ICL | ICL Group Ltd | 90% | Reciprocal relationship from ICL graph: Reciprocal relationship from RANI graph: Reciprocal relationship from ICL graph: Reciprocal relationship from RANI graph: Reciprocal relationship from ICL grap… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from RANI graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, … |
| JNJ | Johnson & Johnson | 72% | entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreemen… |
| LLY | Eli Lilly and Company | 72% | entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter… |
| NVO | Novo Nordisk A/S | 72% | entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreemen… |
| ORANY | ORANY | 72% | uct. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Biologics manufacturers and their subcontractors are required to register t… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from RANI graph: uct. The FDA regulations require that products be manufactured in specific approved facilities and in accordance wit… |
| PTGX | Protagonist Therapeutics, Inc. | 72% | Reciprocal relationship from PTGX graph: Reciprocal relationship from RANI graph: Reciprocal relationship from PTGX graph: Reciprocal relationship from RANI graph: Reciprocal relationship from PTGX g… |
| PTGX | Protagonist Therapeutics, Inc. | 72% | entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CHUGAI | CHUGAI | 92% | the exclusive license granted to Chugai, technology transfer of a sterile manufacturing process, sales-based milestones, and royalties are accounted for under ASC 606 |
| CHUGAI-PHARMACEUTICAL-CO-LTD | CHUGAI-PHARMACEUTICAL-CO-LTD | 85% | rued professional fees 851 718 Accrued rent 328 335 Accrued preclinical and clinical trial costs — 198 Other 97 46 Total accrued expenses and other current liabilities $ 4,706 $ 3,943 6. Evaluation, … |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreemen… |
| JNJ | Johnson & Johnson | 72% | entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreemen… |
| LLY | Eli Lilly and Company | 72% | entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from RANI graph: Reciprocal relationship from NVO graph: Reciprocal relationship from RANI graph: Reciprocal relationship from NVO grap… |
| NVO | Novo Nordisk A/S | 72% | entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from RANI graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from RANI graph: Reciprocal relationship from ORAN… |
| ORANY | ORANY | 72% | uct. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Biologics manufacturers and their subcontractors are required to register t… |
| PTGX | Protagonist Therapeutics, Inc. | 72% | Reciprocal relationship from PTGX graph: Reciprocal relationship from RANI graph: entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreeme… |
| PTGX | Protagonist Therapeutics, Inc. | 72% | entations, warranties and covenants, and mutual indemnification provisions. We have a right to terminate each agreement for convenience subject to certain notice periods. Celltrion has a right to ter… |
| AMENDED-RANI-LLC | AMENDED-RANI-LLC | 62% | ted States, Canada, Europe (including the United Kingdom) and Australia, and ProGen will lead development and commercialization in all other countries. Each party has the right to opt-out of the Coll… |
| AMENDED-RANI-LLC-AGREEMENT-RANI-LLC | AMENDED-RANI-LLC-AGREEMENT-RANI-LLC | 62% | sion of $ 6.0 million of the previously outstanding loan's principal balance), before deducting placement agent fees and other expenses payable by the Company of approximately $ 4.5 million, and excl… |
| INCUBE-LABS-LLC | INCUBE-LABS-LLC | 62% | ently on the market with convenient, oral dosing. We do not have any products approved for sale, and we have not yet generated any revenue from sales of a commercial product. Our ability to generate … |
| PROGEN-CO-LTD | PROGEN-CO-LTD | 62% | llaboration and License Agreement at will, without cause, by providing the Company with 60 days’ prior written notice. Upon termination, Chugai must wind down development, regulatory, and commercial … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| RANI-DEBT-12047 | Warrants outstanding: 3 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| RANI-DEBT | Debt stack $3.9M | 90% | Market cache reports total debt of $3.9M. |
| RANI-DEBT-12048 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| RANI-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 75 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ICL | ICL Group Ltd | 100.00 | 1 | ['supplier'] |
| LLY | Eli Lilly and Company | 100.00 | 1 | ['customer', 'supplier'] |
| NVO | Novo Nordisk A/S | 100.00 | 1 | ['customer', 'supplier'] |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| PTGX | Protagonist Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| JNJ | Johnson & Johnson | 100.00 | 1 | ['customer', 'supplier'] |
| CHUGAI | CHUGAI | 63.48 | 1 | ['receiving'] |
| ASBPW | Aspire Biopharma Holdings, Inc. | 50.00 | 2 | |
| BLTE | Belite Bio, Inc | 50.00 | 2 | |
| BCDRF | Banco Santander, S.A. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| ARQQW | Arqit Quantum Inc. | 50.00 | 2 | |
| BFRIW | Biofrontera Inc. | 50.00 | 2 | |
| AMXOF | AMERICA MOVIL SAB DE CV/ | 50.00 | 2 | |
| BLNK | Blink Charging Co. | 50.00 | 2 | |
| CMCM | Cheetah Mobile Inc. | 50.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 |